A Phase 3 interventional study of adalimumab in Psoriasis, sponsored by Abbott. Completed at 104 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-04-13.
Sponsored by Abbott · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies testing adalimumab in Psoriasis — 6 open to participants now, 6 under way, 1 of them phase 3. Adalimumab · Psoriasis.
Among the 48 studies testing adalimumab in Psoriasis, this one has the largest enrollment, is one of 2 that started in 2004, is one of 26 in phase 3, and was the 1st registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →6 of the 48 studies testing adalimumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:
South Valley University · Sites in Egypt
Ages 18–70 · Healthy volunteers
Mabscale, LLC · Sites in Russian Federation
Ages 18–65
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Ages 4–17
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 27 · Phase 4 11
First in 2003; this study’s year is marked. 2 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,469 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 148 across the 48 interventional studies. Of the 41 that completed or were terminated, 27 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 48 have an industry lead sponsor. The 10 most frequent:
Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.
16 studies in Psoriasis by Abbott: none open now, none under way, none of them phase 3. Of 15 finished, 8 (53%) have results posted.
Among the 16 studies in Psoriasis by Abbott, this one has the largest enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2004, is one of 6 in phase 3, and was the 1st registered.
Abbott’s Psoriasis studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 48 studies testing adalimumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Abbott’s 16 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The two objectives of this study were to evaluate long-term efficacy and safety of adalimumab treatment in participants who had moderate to severe chronic plaque psoriasis and to evaluate the effectiveness of adalimumab retreatment in participants who had therapeutic response to adalimumab and were then withdrawn from adalimumab treatment.
Study M03-658 was a continuation study for participants with moderate to severe psoriasis who had participated in a prior psoriasis adalimumab study. Study M03-658 consisted of three sequential treatment periods. The first period was Period O, in which participants received open-label treatment with adalimumab (40 mg every other week or 40 mg every week) for a minimum of 104 weeks and a maximum of 252 weeks. Period O was the only period of the study until May 2008, when the subsequent periods were added via amendment to the protocol. At that time, participants who had achieved satisfactory therapeutic response (a Physician's Global Assessment [PGA] of 0, 1, or 2 [clear, minimal, or mild]) were given the opportunity to discontinue from the study or to continue and participate in the subsequent two periods. The second period was Period W, a maximum of 52 weeks, in which participants with a PGA of 2 (mild) or less were withdrawn from adalimumab treatment (i.e., participants received no treatment) until relapse of their psoriasis occurred (defined as a PGA of 3 [moderate] or worse). The third period was Period R, a 16-week period in which participants were retreated with open-label adalimumab (80 mg initial dose followed by 40 mg every other week). Period O was designed to evaluate the first objective regarding long-term efficacy and safety of adalimumab treatment, and Period R was designed to evaluate the effectiveness of adalimumab retreatment following relapse. Specific subsets of the study population that were identified as the populations of interest were the modified intent-to-treat populations for Period W and Period R, and these are described further in the outcome measures.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: adalimumab
40 mg every other week or 40 mg every week by subcutaneous injection
Also known as: ABT-D2E7, Humira
Percentage of Participants With a Physician's Global Assessment of Clear or Minimal at Week 16 of Period R
The Physician's Global Assessment \[PGA\] was scored by the physician using a 6-point scale (0-5) for the degree of overall lesion severity, where 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, and 5 = very severe. Subjects with a PGA of Clear or Minimal overall lesion severity had scores of 0 or 1.
Time frame: Week 16 of Period R
Percentage of Participants With a Physician's Global Assessment of Clear or Minimal at Week 60
The Physician's Global Assessment \[PGA\] was scored by the physician using a 6-point scale (0-5) for the degree of overall lesion severity, where 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, and 5 = very severe. Subjects with a PGA of Clear or Minimal overall lesion severity had scores of 0 or 1.
Time frame: Week 60
Percentage of Participants With a Physician's Global Assessment of Clear or Minimal at Week 120
The Physician's Global Assessment \[PGA\] was scored by the physician using a 6-point scale (0-5) for the degree of overall lesion severity, where 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, and 5 = very severe. Subjects with a PGA of Clear or Minimal overall lesion severity had scores of 0 or 1.
Time frame: Week 120
Percentage of Participants Who Achieved a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 60
Psoriasis Area and Severity Index (PASI) scores were calculated from assessments at 4 designated anatomical sites (head, upper extremities, trunk, lower extremities) using both severity and area subscores (i.e., degree of and amount of psoriatic involvement per site). PASI scores range from 0.0 (best) to 72.0 (worst), with the highest score representing complete erythroderma of the severest degree. Positive percent decreases indicate improvement, with the best improvement being 100%. A PASI 75 response was at least a 75% reduction in PASI score from baseline PASI score of the initial study.
Time frame: Week 60
Percentage of Participants Who Achieved a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 120
Psoriasis Area and Severity Index (PASI) scores were calculated from assessments at 4 designated anatomical sites (head, upper extremities, trunk, lower extremities) using both severity and area subscores (i.e., degree of and amount of psoriatic involvement per site). PASI scores range from 0.0 (best) to 72.0 (worst), with the highest score representing complete erythroderma of the severest degree. Positive percent decreases indicate improvement, with the best improvement being 100%. A PASI 75 response was at least a 75% reduction in PASI score from baseline PASI score of the initial study.
Time frame: Week 120
Time to Relapse in Period W
Relapse of psoriasis was defined as a Physician's Global Assessment (assessment of overall lesion severity) score of greater than or equal to 3 (3=moderate; 4=severe; 5=very severe).
Time frame: Period W
Percentage of Period R Modified Intent-to-Treat Participants Who Relapsed in Period W and Subsequently Had a Physician's Global Assessment of Clear or Minimal at Week 16 of Period R
The Physician's Global Assessment \[PGA\] was scored by the physician using a 6-point scale (0-5) for the degree of overall lesion severity, where 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, and 5 = very severe. Subjects with a PGA of Clear or Minimal overall lesion severity had scores of 0 or 1.
Time frame: Week 16 of Period R
Percentage of Period R Modified Intent-to-Treat Participants Who Did Not Relapse in Period W and Subsequently Had a Physician's Global Assessment of Clear or Minimal at Week 16 of Period R
The Physician's Global Assessment \[PGA\] was scored by the physician using a 6-point scale (0-5) for the degree of overall lesion severity, where 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, and 5 = very severe. Subjects with a PGA of Clear or Minimal overall lesion severity had scores of 0 or 1.
Time frame: Week 16 of Period R
| Milestone | All Adalimumab Treatment |
|---|---|
| Started | 1468 |
| Completed | 862 |
| Not completed | 606 |
| Withdrew: Adverse event | 82 |
| Withdrew: Death | 6 |
| Withdrew: Lack of efficacy | 198 |
| Withdrew: Lost to follow-up | 91 |
| Withdrew: Protocol violation | 12 |
| Withdrew: Withdrawal by subject | 147 |
| Withdrew: Administrative reasons | 2 |
| Withdrew: Other reasons | 68 |
| Milestone | All Adalimumab Treatment |
|---|---|
| Started | 608 |
| Completed | 0 |
| Not completed | 608 |
| Withdrew: Adverse event | 4 |
| Withdrew: Death | 2 |
| Withdrew: Lost to follow-up | 11 |
| Withdrew: Withdrawal by subject | 46 |
| Withdrew: Relapse (pga >= 3) | 397 |
| Withdrew: Period w close-out | 129 |
| Withdrew: Administrative reasons | 1 |
| Withdrew: Other reasons | 18 |
| Milestone | All Adalimumab Treatment |
|---|---|
| Started | 525 |
| Completed | 490 |
| Not completed | 35 |
| Withdrew: Adverse event | 4 |
| Withdrew: Lack of efficacy | 5 |
| Withdrew: Lost to follow-up | 11 |
| Withdrew: Withdrawal by subject | 9 |
| Withdrew: Other reasons | 6 |
The Physician's Global Assessment \[PGA\] was scored by the physician using a 6-point scale (0-5) for the degree of overall lesion severity, where 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, and 5 = very severe. Subjects with a PGA of Clear or Minimal overall lesion severity had scores of 0 or 1.
| percentage of participants | Period O Adalimumab EOW Treatment Population |
|---|---|
| Percentage of Participants With a Physician's Global Assessment of Clear or Minimal at Week 60 | 50.6 |
The Physician's Global Assessment \[PGA\] was scored by the physician using a 6-point scale (0-5) for the degree of overall lesion severity, where 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, and 5 = very severe. Subjects with a PGA of Clear or Minimal overall lesion severity had scores of 0 or 1.
| percentage of participants | Period O Adalimumab EOW Treatment Population |
|---|---|
| Percentage of Participants With a Physician's Global Assessment of Clear or Minimal at Week 120 | 46.3 |
The Physician's Global Assessment \[PGA\] was scored by the physician using a 6-point scale (0-5) for the degree of overall lesion severity, where 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, and 5 = very severe. Subjects with a PGA of Clear or Minimal overall lesion severity had scores of 0 or 1.
| percentage of participants | Period R Modified Intent-to-Treat Population |
|---|---|
| Percentage of Participants With a Physician's Global Assessment of Clear or Minimal at Week 16 of Period R | 76.5 |
Psoriasis Area and Severity Index (PASI) scores were calculated from assessments at 4 designated anatomical sites (head, upper extremities, trunk, lower extremities) using both severity and area subscores (i.e., degree of and amount of psoriatic involvement per site). PASI scores range from 0.0 (best) to 72.0 (worst), with the highest score representing complete erythroderma of the severest degree. Positive percent decreases indicate improvement, with the best improvement being 100%. A PASI 75 response was at least a 75% reduction in PASI score from baseline PASI score of the initial study.
| percentage of participants | Period O Adalimumab EOW Treatment Population |
|---|---|
| Percentage of Participants Who Achieved a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 60 | 61.4 |
Psoriasis Area and Severity Index (PASI) scores were calculated from assessments at 4 designated anatomical sites (head, upper extremities, trunk, lower extremities) using both severity and area subscores (i.e., degree of and amount of psoriatic involvement per site). PASI scores range from 0.0 (best) to 72.0 (worst), with the highest score representing complete erythroderma of the severest degree. Positive percent decreases indicate improvement, with the best improvement being 100%. A PASI 75 response was at least a 75% reduction in PASI score from baseline PASI score of the initial study.
| percentage of participants | Period O Adalimumab EOW Treatment Population |
|---|---|
| Percentage of Participants Who Achieved a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 120 | 57.3 |
Relapse of psoriasis was defined as a Physician's Global Assessment (assessment of overall lesion severity) score of greater than or equal to 3 (3=moderate; 4=severe; 5=very severe).
| days | Period W Modified Intent-to-treat Population |
|---|---|
| Time to Relapse in Period W | 141 (127 to 146) |
The Physician's Global Assessment \[PGA\] was scored by the physician using a 6-point scale (0-5) for the degree of overall lesion severity, where 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, and 5 = very severe. Subjects with a PGA of Clear or Minimal overall lesion severity had scores of 0 or 1.
| percentage of participants | Period R mITT Population Relapsed in Period W |
|---|---|
| Percentage of Period R Modified Intent-to-Treat Participants Who Relapsed in Period W and Subsequently Had a Physician's Global Assessment of Clear or Minimal at Week 16 of Period R | 69.1 |
The Physician's Global Assessment \[PGA\] was scored by the physician using a 6-point scale (0-5) for the degree of overall lesion severity, where 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, and 5 = very severe. Subjects with a PGA of Clear or Minimal overall lesion severity had scores of 0 or 1.
| percentage of participants | Period R Modified Intent-to-Treat Not Relapsed in Period W |
|---|---|
| Percentage of Period R Modified Intent-to-Treat Participants Who Did Not Relapse in Period W and Subsequently Had a Physician's Global Assessment of Clear or Minimal at Week 16 of Period R | 88.8 |
Collected over 2,095 days(approximately 5.7 years), including adalimumab exposure in prior studies. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Adalimumab Treatment | — | 189/1,468 (12.9%) | 1,036/1,468 (70.6%) |
| Event | All Adalimumab Treatment |
|---|---|
| Coronary artery diseaseCardiac disorders | 10/1468 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 8/1468 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 7/1468 |
| CellulitisInfections and infestations | 6/1468 |
| Myocardial infarctionCardiac disorders | 5/1468 |
| PneumoniaInfections and infestations | 5/1468 |
| NephrolithiasisRenal and urinary disorders | 5/1468 |
| InjuryInjury, poisoning and procedural complications | 4/1468 |
| ObesityMetabolism and nutrition disorders | 4/1468 |
| DepressionPsychiatric disorders | 4/1468 |
| Event | All Adalimumab Treatment |
|---|---|
| NasopharyngitisInfections and infestations | 391/1468 |
| Upper respiratory tract infectionInfections and infestations | 298/1468 |
| HeadacheNervous system disorders | 164/1468 |
| HypertensionVascular disorders | 163/1468 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 156/1468 |
| SinusitisInfections and infestations | 150/1468 |
| BronchitisInfections and infestations | 116/1468 |
| InfluenzaInfections and infestations | 113/1468 |
| Back painMusculoskeletal and connective tissue disorders | 110/1468 |
| CoughRespiratory, thoracic and mediastinal disorders | 94/1468 |
| Age Continuous(years) | All Adalimumab Treatment |
|---|---|
| Mean | 44.1 ± 12.75 |
| Sex: Female, Male(Participants) | All Adalimumab Treatment |
|---|---|
| Female | 470 |
| Male | 998 |
| Region of Enrollment(participants) | All Adalimumab Treatment |
|---|---|
| United States | 802 |
| Canada | 501 |
| Austria | 34 |
| Belgium | 15 |
| France | 45 |
| Switzerland | 3 |
| Spain | 20 |
| Poland | 12 |
| Germany | 36 |
Showing the first 100 of 104 sites across 10 countries. Choose a country and city above to see the rest.
The record gives a start of May 2004, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2010, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab